How to improve antibiotic awareness campaigns: findings of a WHO global survey.

World Health Organization anti-bacterial agents awareness bacterial drug resistance drug resistance, bacterial global health health communication health education

Journal

BMJ global health
ISSN: 2059-7908
Titre abrégé: BMJ Glob Health
Pays: England
ID NLM: 101685275

Informations de publication

Date de publication:
2019
Historique:
received: 21 10 2018
revised: 15 01 2019
accepted: 19 01 2019
entrez: 11 6 2019
pubmed: 11 6 2019
medline: 11 6 2019
Statut: epublish

Résumé

We aimed to examine the characteristics of antibiotic awareness campaigns (AAC) conducted on a national or regional level since 2010. In October 2016, the WHO invited stakeholders involved in the planning or conduct of AACs to answer a web questionnaire. We solicited general information about the characteristics of the AAC, with a particular focus on key messages supporting optimal use of antibiotics. Stakeholders in 93 countries were contacted and 55 countries responded. Overall, 60 AACs from 16 low/middle-income countries (LMIC) and 31 high-income countries were identified. Forty-five campaigns (75%) were conducted on a national level and most of them (47/60; 78%) were organised by public health authorities and publicly funded. There were no major differences between LMICs and high-income countries in the types of key messages. The scientifically questionable 'Finish your prescription' slogan was used by 31 AACs (52%). A One Health approach was mentioned in 13/60 AACs (22%). Most messages were universally applicable; adaptation to locally prevalent public misconceptions was not systematic. The evaluation of the impact of campaigns was still incomplete, as only 18 AACs (30%) assessed their impact on antibiotic use. For future AACs, it seems essential to base messages more rigorously on scientific evidence, context specificities and behavioural change theory. A new generation of messages that encourage first-choice use of narrow spectrum antibiotics is needed, reflecting international efforts to preserve broad spectrum antibiotic classes. Evaluation of the impact of AACs remains suboptimal.

Identifiants

pubmed: 31179029
doi: 10.1136/bmjgh-2018-001239
pii: bmjgh-2018-001239
pmc: PMC6528771
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e001239

Déclaration de conflit d'intérêts

Competing interests: SH is a temporary member of the speakers’ bureau for Takeda and the scientific advisory boards of DNA Electronics, Sandoz and Bayer. He has received financial support for investigator-initiated research activities from Pfizer.

Références

Infect Control Hosp Epidemiol. 2015 Feb;36(2):142-52
pubmed: 25632996
Eur J Health Econ. 2013 Aug;14(4):587-99
pubmed: 22706960
Expert Rev Anti Infect Ther. 2016;14(4):403-13
pubmed: 26853235
S Afr Med J. 2015 Apr 06;105(5):325
pubmed: 26242647
Health Educ Res. 2009 Jun;24(3):483-95
pubmed: 18948569
Cochrane Database Syst Rev. 2013 Jun 06;(6):CD004704
pubmed: 23744348
Lancet Infect Dis. 2018 Jan;18(1):18-20
pubmed: 29303731
Clin Microbiol Rev. 2013 Apr;26(2):289-307
pubmed: 23554418
BMC Fam Pract. 2016 Nov 3;17(1):148
pubmed: 27809770
Antimicrob Agents Chemother. 2014;58(1):71-7
pubmed: 24126584
J Nutr Educ Behav. 2007 Mar-Apr;39(2 Suppl):S5-12
pubmed: 17336806
JAMA Intern Med. 2016 Sep 1;176(9):1254-5
pubmed: 27455385
JAMA. 2016 Nov 22;316(20):2115-2125
pubmed: 27893129
J Antimicrob Chemother. 2018 Jun 1;73(6):1464-1478
pubmed: 29554263
J Antimicrob Chemother. 2011 Dec;66(12):2872-9
pubmed: 21965428
Curr Opin Pharmacol. 2011 Oct;11(5):446-52
pubmed: 21775205
BMJ. 2017 Jul 26;358:j3418
pubmed: 28747365
Nat Rev Urol. 2017 Mar;14(3):139-152
pubmed: 28072403
J Antimicrob Chemother. 2016 Jan;71(1):27-33
pubmed: 26459555
Lancet Infect Dis. 2010 Jan;10(1):17-31
pubmed: 20129146
Emerg Infect Dis. 2008 Nov;14(11):1722-30
pubmed: 18976555
JAMA. 2016 May 3;315(17):1864-73
pubmed: 27139059
Antimicrob Resist Infect Control. 2016 Oct 20;5:39
pubmed: 27777760
Euro Surveill. 2014 Oct 16;19(41):
pubmed: 25345519
N Engl J Med. 2013 Dec 26;369(26):2474-6
pubmed: 24369073
Clin Microbiol Infect. 2008 Apr;14(4):298-306
pubmed: 18093237
J Antimicrob Chemother. 2017 Apr 1;72(4):975-987
pubmed: 27999058
Cochrane Database Syst Rev. 2011 Dec 07;(12):CD006777
pubmed: 22161408
J Antimicrob Chemother. 2010 Jul;65(7):1526-33
pubmed: 20488985
BMC Public Health. 2014 Jun 18;14:616
pubmed: 24939013
Emerg Infect Dis. 2002 Dec;8(12):1460-7
pubmed: 12498664
BMJ. 2013 Sep 12;347:f5391
pubmed: 24030722
J Antimicrob Chemother. 2017 Jan;72(1):311-314
pubmed: 27655854
BMC Infect Dis. 2015 Nov 25;15:545
pubmed: 26607324
J Antimicrob Chemother. 2018 Jun 1;73(suppl_6):vi17-vi29
pubmed: 29878219
J Med Internet Res. 2015 Oct 15;17(10):e233
pubmed: 26471079
Lancet. 2016 Jan 9;387(10014):176-87
pubmed: 26603922
Cochrane Database Syst Rev. 2017 Feb 09;2:CD003543
pubmed: 28178770
Clin Infect Dis. 2016 Feb 1;62(3):403-4
pubmed: 26433719
N Engl J Med. 2006 Apr 6;354(14):1455-63
pubmed: 16598044
PLoS One. 2014 Aug 27;9(8):e104556
pubmed: 25162505
Proc Biol Sci. 2014 Nov 7;281(1794):20140566
pubmed: 25253451
Curr Drug Saf. 2010 Oct;5(4):329-32
pubmed: 20615180
J Antimicrob Chemother. 2012 Mar;67(3):763-7
pubmed: 22200725
BMJ. 2016 Mar 15;352:i939
pubmed: 26980184
Lancet Infect Dis. 2008 Dec;8(12):785-95
pubmed: 19022193
Clin Infect Dis. 2009 Sep 1;49(5):750-6
pubmed: 19624280
J Health Commun. 2015;20(12):1433-40
pubmed: 26181623
Br J Gen Pract. 2013 Jul;63(612):e429-36
pubmed: 23834879

Auteurs

Benedikt Huttner (B)

Infection Control Program and Division of Infectious Diseases, World Health Organization Collaborating Centre on Patient Safety, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
World Health Organization, Department of Essential Medicines and Health Products, World Health Organization, Geneva, Switzerland.

Mirko Saam (M)

Communications in Science, Geneva, Switzerland.

Lorenzo Moja (L)

World Health Organization, Department of Essential Medicines and Health Products, World Health Organization, Geneva, Switzerland.

Karen Mah (K)

World Health Organization, Antimicrobial Resistance Secretariat, Geneva, Switzerland.

Marc Sprenger (M)

World Health Organization, Antimicrobial Resistance Secretariat, Geneva, Switzerland.

Stephan Harbarth (S)

Infection Control Program and Division of Infectious Diseases, World Health Organization Collaborating Centre on Patient Safety, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Nicola Magrini (N)

World Health Organization, Department of Essential Medicines and Health Products, World Health Organization, Geneva, Switzerland.

Classifications MeSH